Wednesday, 16 October 2024
  
Login

Australia's most trusted
source of pharma news

Wednesday, 16 October 2024
News

Who's blown away the competition?

 Posted 15 October 2024 AM

ASX-listed LTR Pharma has announced remarkable results from the completed pivotal clinical study for its erectile dysfunction nasal spray Spontan, showing a 470 per cent faster absorption rate compared to oral treatments, and positioning the product as a potential global market disruptor.

The results have bolstered LTR's commercialisation prospects with the company in ongoing global partnering and licensing discussions. Additionally, the data will support LTR's engagement with key regulatory bodies, including the FDA and TGA.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Clinical & Medical, R&D (17)

Regulatory, Pharmacovigilance & QA (7)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.